Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcus Renner

Showing results (21-30 of 65) with videos related to

Pageof 7
Sort By:
Histopathology|January 29, 2017
DMBT1 expression in biliary carcinogenesis with correlation of clinicopathological dataBenjamin Goeppert, Stephanie Roessler, Natalia Becker, et al.
British Journal of Cancer|October 14, 2015
Major histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary tract cancerBenjamin Goeppert, Lena Frauenschuh, Manuela Zucknick, et al.
Respiratory Research|October 3, 2007
Deleted in Malignant Brain Tumors 1 (DMBT1) is present in hyaline membranes and modulates surface tension of surfactantHanna Müller, Caroline End, Marcus Renner, et al.
Protein Expression and Purification|May 4, 2005
Generation of a vector system facilitating cloning of DMBT1 variants and recombinant expression of functional full-length DMBT1Caroline End, Stefan Lyer, Marcus Renner, et al.
Histopathology|August 21, 2015
Differential nuclear ATRX expression in sarcomasChristian Koelsche, Marcus Renner, Pascal Johann, et al.
Proteomics. Clinical Applications|February 1, 2020
Microproteomics and Immunohistochemistry Reveal Differences in Aldo-Keto Reductase Family 1 Member C3 in Tissue Specimens of Ulcerative Colitis and Crohn's DiseaseKarim Arafah, Mark Kriegsmann, Marcus Renner, et al.
Histopathology|February 3, 2012
Increased levels of deleted in malignant brain tumours 1 (DMBT1) in active bacteria-related appendicitisElke Kaemmerer, Ursula Schneider, Christina Klaus, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 15, 2014
TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entitiesChristian Koelsche, Marcus Renner, Wolfgang Hartmann, et al.
Der Pathologe|October 4, 2021
Peter Horak, Jonas Leichsenring, Simon Kreutzfeldt, et al.
Der Pathologe|May 3, 2021
[Variant interpretation in molecular pathology and oncology : An introduction]Peter Horak, Jonas Leichsenring, Simon Kreutzfeldt, et al.
Pageof 7

Showing results (21-30 of 65) with videos related to

Sort By:
Pageof 7
Histopathology|January 29, 2017
DMBT1 expression in biliary carcinogenesis with correlation of clinicopathological dataBenjamin Goeppert, Stephanie Roessler, Natalia Becker, et al.
British Journal of Cancer|October 14, 2015
Major histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary tract cancerBenjamin Goeppert, Lena Frauenschuh, Manuela Zucknick, et al.
Respiratory Research|October 3, 2007
Deleted in Malignant Brain Tumors 1 (DMBT1) is present in hyaline membranes and modulates surface tension of surfactantHanna Müller, Caroline End, Marcus Renner, et al.
Protein Expression and Purification|May 4, 2005
Generation of a vector system facilitating cloning of DMBT1 variants and recombinant expression of functional full-length DMBT1Caroline End, Stefan Lyer, Marcus Renner, et al.
Histopathology|August 21, 2015
Differential nuclear ATRX expression in sarcomasChristian Koelsche, Marcus Renner, Pascal Johann, et al.
Proteomics. Clinical Applications|February 1, 2020
Microproteomics and Immunohistochemistry Reveal Differences in Aldo-Keto Reductase Family 1 Member C3 in Tissue Specimens of Ulcerative Colitis and Crohn's DiseaseKarim Arafah, Mark Kriegsmann, Marcus Renner, et al.
Histopathology|February 3, 2012
Increased levels of deleted in malignant brain tumours 1 (DMBT1) in active bacteria-related appendicitisElke Kaemmerer, Ursula Schneider, Christina Klaus, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 15, 2014
TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entitiesChristian Koelsche, Marcus Renner, Wolfgang Hartmann, et al.
Der Pathologe|October 4, 2021
Peter Horak, Jonas Leichsenring, Simon Kreutzfeldt, et al.
Der Pathologe|May 3, 2021
[Variant interpretation in molecular pathology and oncology : An introduction]Peter Horak, Jonas Leichsenring, Simon Kreutzfeldt, et al.
Pageof 7